| abstract |
The present invention relates to gastrointestinal immune related adverse events such as colitis and diarrhea, among others, in immunotherapy such as cancer immunotherapy, for example in a subject receiving combination therapy with anti-CTLA4 antibody and anti-PD-1 antibody for melanoma Provide a way to reduce In certain embodiments, the method comprises administering a therapeutically effective amount of a polypeptide that inhibits MAdCAM-integrin binding, eg, an anti-α4β7 integrin antibody such as vedolizumab or related antibodies. |